Latest news

Blue-Earth logo 900400.jpg 1 June 2023

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval for its optimized, high-affinity radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent, POSLUMA® (flotufolastat F 18) injection (formerly referred to as 18F-rhPSMA-7.3)

Read more
PentixaPharm thumbnail news.jpg 19 April 2021

Eckert & Ziegler Strahlen- und Medizintechnik AG Acquires Direct Majority Stake in Drug Developer PENTIXAPHARM

Würzburg (Germany), April 19th, 2021 – Eckert & Ziegler Strahlen- und Medizintechnik AG has acquired several share packages from the founders of PentixaPharm GmbH. Together with another internal share transfer, Eckert & Ziegler AG will directly hold a total of about 83% of the shares in the company as of closing of the transactions.

Read more
Blue-Earth logo 900400.jpg 5 January 2021

Blue Earth Diagnostics Acquires Exclusive, Worldwide Rights to Therapeutic Applications of Scintomics’ Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) Technology for Prostate Cancer

Blue Earth Diagnostics has exercised an option to acquire exclusive, worldwide rights to therapeutic applications of novel radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) technology in prostate cancer

Read more
Header_news_point_thumbnail.jpg 10 March 2020

POINT Biopharma and SCINTOMICS Announce License Agreement

POINT Biopharma Inc. today announced that it has entered into an agreement with SCINTOMICS GmbH for the exclusive use and development of a family of more than seventy patented next generation PSMA radioligands for targeted radiotherapy of prostate cancer.

Read more
PentixaPharm thumbnail news.jpg 6 February 2020

PENTIXAPHARM Secures € 15 Million Series A Financing to Develop CXCR4-Targeted Theranostics

Feburary 6th 2020, WÜRZBURG, Germany--PentixaPharm announced today to have secured € 15 million in a series A financing round led by ELSA Eckert Life Science Accelerator.

Read more
technische-universitat-munchen-tum-logo.png 3 July 2019

Scintomics gewinnt TUM Presidential Entrepreneurship Award

Scintomics hat den diesjährigen TUM Presidential Entrepreneurship Award gewonnen. Das Unternehmen entwickelt radiopharmazeutische Technologien zur Krebsdiagnose.

Read more